Literature DB >> 19285071

Edaravone in ALS.

Ryosuke Takahashi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19285071     DOI： 10.1016/j.expneurol.2009.03.001

Source DB:  PubMed          Journal:  Exp Neurol        ISSN： 0014-4886            Impact factor:   5.330


× No keyword cloud information.
  3 in total

1.  Neuroprotective effect of edaravone in experimental glaucoma model in rats: a immunofluorescence and biochemical analysis.

Authors:  Arzu Toruk Aksar; Nursen Yuksel; Mustafa Gok; Mustafa Cekmen; Yusuf Caglar
Journal:  Int J Ophthalmol       Date:  2015-04-18       Impact factor: 1.779

2.  Potential of edaravone for neuroprotection in neurologic diseases that do not involve cerebral infarction.

Authors:  Kiyoshi Kikuchi; Ko-Ichi Kawahara; Hisaaki Uchikado; Naohisa Miyagi; Terukazu Kuramoto; Tomoya Miyagi; Yoko Morimoto; Takashi Ito; Salunya Tancharoen; Naoki Miura; Kazunori Takenouchi; Yoko Oyama; Binita Shrestha; Fumiyo Matsuda; Yoshihiro Yoshida; Shinihiro Arimura; Kentaro Mera; Ko-Ichi Tada; Narimasa Yoshinaga; Ryuichi Maenosono; Yoshiko Ohno; Teruto Hashiguchi; Ikuro Maruyama; Minoru Shigemori
Journal:  Exp Ther Med       Date:  2011-06-07       Impact factor: 2.447

3.  Effects of edaravone on amyloid-β precursor protein processing in SY5Y-APP695 cells.

Authors:  Yue-E Shen; Yan Wang; Gui-Chun Yu; Chao Liu; Zhen-Yu Zhang; Li-Ming Zhang
Journal:  Neurotox Res       Date:  2013-01-17       Impact factor: 3.911
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.